Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

RecruitingLast updated: 30 April 2026

MOSES-Survivorship: Testing new ways of delivering follow-up care for people with prostate cancer to see if these improve quality of life and the health care experienceA hybrid, implementation-effectiveness trial of a nurse-enabled, shared-care MOdel between primary and acute care for proStatE cancer Survivors

Trial purpose

Medical clipboardEducation, training or system changes; Side effect and wellbeing

Tumor type

Urinary System Cancers Genitourinary

Age

People18+

Trial acronym

MOSES-Survivorship

Clinical summary

Summary

The purpose of this study is to implement and test the effectiveness of a new care model that will be coordinated by specialist cancer nurses while also involving medical specialists (surgeons, oncologists, and general practioners (GPs)) for follow-up care of people with prostate cancer.

Who is it for?
You may be eligible for this study if you are aged 18 years and older and have prostate cancer. This includes those who have:

  • localised prostate cancer and are being monitored through active surveillance
  • localised prostate cancer (low, intermediate, or high risk) and have completed their primary curative intent treatment (surgery or radiation therapy) within the past 3 years, or
  • had a diagnosis of metastatic prostate cancer for at least 3 months or more.

Study details
Participants in this study will be randomly allocated (by chance) to one of two groups.

Participants in one group will be receiving usual, specialist-led follow-up care and information from Cancer Council Australia for up to 5 years.

The other group will undergo the nurse-coordinated care model. This involves a series of 30 to 60 minute appointments with specialist nurses, GPs or hospital cancer specialists every 6 months for up to 5 years. 

As part of the study all participants will answer a series of questionnaires as baseline, 6 months, and 12 months.

It is hoped this research will demonstrate that the new model of care increases patient quality of life and health care experience and improve prostate cancer follow-up care.

Conditions

This trial is treating people with prostate cancer

Eligibility

Inclusion

Men with confirmed adenocarcinoma of the prostate (i.e., men with prostate cancer), who have (a) localised prostate cancer and being monitored through active surveillance, (b) localised prostate cancer (low, intermediate, or high risk) and have completed their primary curative intent treatment (surgery or radiation therapy) within the past 3 years, or (c) have had a diagnosis of metastatic prostate cancer for at-least 3 months or more.

Men must be 18 years of age or older; be able or willing to identify a usual GP or General Practice; be ambulatory with a Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2; have access to a telephone; and be-able to speak and read English.

Exclusion

People will be excluded if they do not have prostate cancer; present with severe mental, cognitive or physical conditions or other circumstance that would limit the patient’s ability to participate at the discretion of treating clinicians; are judged to have <6 months of life expectancy at the discretion of the treating cancer specialist (urologist/oncologist); or who are unable to provide consent.

Inclusion

  • Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
  • Your cancer has not spread to other parts of the body (localised).
  • You have the type of cancer, symptoms, or health risks that this clinical trial is focused on.

Exclusion

  • You have certain types of non-cancer medical conditions.
Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ANZCTR *. View further details about this trial on the registry via the links below:

Trial sponsor

Professor Raymond Chan

Scientific Title

A hybrid, implementation-effectiveness trial of a nurse-enabled, shared-care MOdel between primary and acute care for proStatE cancer Survivors

Get Support

Peer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Peer Connect

Contact cancer support

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information